General Information of Drug (ID: DMD7K9X)

Drug Name
Davunetide Drug Info
Synonyms
Davunetide; NAP; AL-108; AL-208; Davunetide (intranasal spray), Allon; NAPVSIPQ eight amino acid peptide (intranasal spray), Allon; Davunetide (intravenous-infused), Allon Therapeutics; NAP eight amino acid peptide (neuroprotection/cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (neuroprotection/cognitive impairment), Allon; Central nervous system therapeutic (Alzheimer's disease/schizophrenia), Allon; Central nervous system therapeutic (post-cardiac artery bypass graft/mild cognitive impairment), Allon; NAPVSIPQ eight amino acid peptide (intravenous-infused/subcutaneous depot formulation), Allon Therapeutics; Davunetide (iv/sc, Alzheimer's disease), Allon Therapeutics
Indication
Disease Entry ICD 11 Status REF
Cognitive impairment 6D71 Phase 3 [1]
Alzheimer disease 8A20 Discontinued in Phase 2 [2]
Cross-matching ID
PubChem CID
9832404
TTD Drug ID
DMD7K9X

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
LMT-X DMOFIBM Acute myeloid leukaemia 2A60 Phase 3 [3]
TRx0237 DM0QNF4 Alzheimer disease 8A20 Phase 3 [4]
E2814 DMZ3Q59 Alzheimer disease 8A20 Phase 2/3 [5]
PBT-2 DMKWGS1 Alzheimer disease 8A20 Phase 2 [6]
RG6100 DMEFD0B Alzheimer disease 8A20 Phase 2 [7]
Tau-binding PET tracer DM9QFW2 Alzheimer disease 8A20 Phase 2 [1]
BIIB092 DM263RP Progressive supranuclear palsy 8A00.10 Phase 2 [7]
Semorinemab DMA17VD Alzheimer disease 8A20 Phase 2 [8]
Bepranemab DMRQIJO Alzheimer disease 8A20 Phase 2 [9]
JNJ-63733657 DMMKWGJ Alzheimer disease 8A20 Phase 2 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Microtubule-associated protein tau (MAPT) TTS87KH TAU_HUMAN Modulator [1]

References

1 Microtubules (tau) as an emerging therapeutic target: NAP (davunetide). Curr Pharm Des. 2011;17(31):3413-7.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800014948)
3 Clinical pipeline report, company report or official report of TauRx.
4 Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model. Curr Alzheimer Res. 2020;17(3):285-296.
5 Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer's disease. Acta Neuropathol Commun. 2020 Feb 4;8(1):13.
6 PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J Alzheimers Dis. 2010;20(2):509-16.
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease. Sci Transl Med. 2021 May 12;13(593):eabb2639.
9 Immunotherapy for Alzheimer's disease: targeting beta-amyloid and beyond. Transl Neurodegener. 2022 Mar 18;11(1):18.
10 ClinicalTrials.gov (NCT04619420) A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease. U.S.National Institutes of Health.